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versus placebo) in bipolar depression (CEQUEL): a 2 × 2 
factorial randomised trial
John R Geddes, Alexandra Gardiner, Jennifer Rendell, Merryn Voysey, Elizabeth Tunbridge, Christopher Hinds, Ly-Mee Yu, Jane Hainsworth, 
Mary-Jane Attenburrow, Judit Simon, Guy M Goodwin, Paul J Harrison, on behalf of the CEQUEL Investigators and Collaborators*
Summary
Background Depressive symptoms are a major cause of disability in bipolar disorder and there are few safe and 
eff ective treatments. The combination of lamotrigine plus quetiapine potentially off ers improved outcomes for people 
with bipolar depression. We aimed to determine if combination therapy with quetiapine plus lamotrigine leads to 
greater improvement in depressive symptoms over 12 weeks than quetiapine monotherapy plus lamotrigine placebo.
Methods In this double-blind, randomised, placebo-controlled, parallel group, 2 × 2 factorial trial (CEQUEL), patients 
with DSM-IV bipolar disorder I or II, who were aged 16 years or older, and required new treatment for a depressive 
episode, were enrolled from 27 sites in the UK. Patients were randomly assigned (1:1) by an adaptive minimisation 
algorithm to lamotrigine or placebo and to folic acid or placebo. Participants and investigators were masked to the 
treatment groups. The primary outcome was improvement in depressive symptoms at 12 weeks with the Quick 
Inventory of Depressive Symptomatology—self report version 16 (QIDS-SR16). Analysis was by modifi ed intention-
to-treat. This trial is registered with EUdraCT, number 2007-004513-33.
Findings Between Oct 21, 2008, and April 27, 2012, 202 participants were randomly assigned; 101 to lamotrigine and 
101 to placebo. The mean diff erence in QIDS-SR16 total score between the group receiving lamotrigine versus the 
placebo group at 12 weeks was –1·73 ([95% CI –3·57 to 0·11]; p=0·066) and at 52 weeks was –2·69 ([–4·89 to –0·49]; 
p=0·017). Folic acid was not superior to placebo. There was a signifi cant interaction (p=0·028), with folic acid reducing 
the eff ectiveness of lamotrigine at 12 weeks. The mean diff erence on QIDS-SR16 was –4·14 ([95% CI –6·90 to –1·37]; 
p=0·004) for patients receiving lamotrigine without folic acid compared with 0·12 ([–2·58 to 2·82]; p=0·931) for those 
receiving lamotrigine and folic acid.
Interpretation Addition of lamotrigine to quetiapine treatment improved outcomes. Folic acid seems to nullify the 
eff ect of lamotrigine. CEQUEL should encourage clinicians and patients to consider lamotrigine for bipolar 
depression, but also to be aware that concurrent folic acid  might reduce its eff ectiveness.
Funding Medical Research Council.
Copyright © Geddes et al. Open Access article distributed under the terms of CC BY. 
Introduction
Bipolar disorder, an illness characterised by recurrent 
depressive and manic episodes, is among the most 
important causes of worldwide disability.1 The burden 
of depressive, rather than manic, symptoms causes 
most of the long-term disability and excess mortality in 
people with bipolar disorder.2 Evidence for eff ective 
short-term and longer-term treatment options for 
bipolar depression remain restricted.3 Recent UK 
National Institute for Health and Care Excellence 
guidelines recommend fl uoxetine plus olanzapine 
combination or quetiapine as fi rst-line treatment.4 The 
evidence for antidepressant drugs such as fl uoxetine in 
bipolar depression, however, remains controversial, 
with no consensus that they are either eff ective or safe.5 
Many patients do not respond to these interventions 
and the evidence for effi  cacy and tolerability of longer-
term quetiapine is scarce.3
Lamotrigine is widely used as an antiepileptic. It is an 
inhibitor of voltage-sensitive sodium channels, and is 
thought to work by reducing presynaptic release of 
glutamate, although its mechanism of action in bipolar 
disorder remains unclear.6 Clinical observation of a 
benefi cial eff ect in depression led to investigation in 
bipolar disorder, which showed effi  cacy in the prevention 
of depressive relapse.7 Lamotrigine is now licensed in the 
USA and the European Union for the prevention of relapse 
in patients with bipolar type 1 disorder who have 
predominantly depressive episodes.8 There has been 
considerable uncertainly, however, around the effi  cacy of 
lamotrigine monotherapy in the acute phase of bipolar 
depression. A modest treatment eff ect was observed in 
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pooled analysis, but not seen in individual trials, which 
could be because the trials were of short (8 week) duration 
and lamotrigine requires a lengthy 6-week titration period, 
which means that the participants had been taking a full 
therapeutic dose for only 2 weeks at the time that the 
primary outcome was assessed.9 The LamLit trial noted 
signifi cant benefi t at 8 weeks for the addition of lamotrigine 
to lithium therapy in patients with bipolar depression.10
Current monotherapies for bipolar depression remain 
restricted in terms of both proven effi  cacy and practical 
tolerability, but combinations of treatments might lead to 
improved outcomes. This trial was designed to test the 
hypothesis that a strategy of combining lamotrigine with 
quetiapine might lead to better short-term response and 
longer-term outcomes than quetiapine alone. Additive 
benefi ts from the combination might, of course, result 
from their independent mechanisms of action, because 
the two drugs have entirely diff erent pharmacologies. 
Further, the rapid onset of the therapeutic eff ects of 
quetiapine could make the slow-dose titration required 
for lamotrigine less problematic: more patients would 
remain on therapy and therefore benefi t from the 
therapeutic potential of lamotrigine in the acute phase. 
There could also be important advantages in the longer 
term since patients on the combination who cannot 
tolerate the known adverse eff ects of quetiapine would 
remain on an eff ective drug following its discontinuation,3 
leading to a functional synergy between lamotrigine and 
quetiapine.
The primary objective was to determine if combination 
therapy with quetiapine plus lamotrigine leads to greater 
improvement in depressive symptoms over 12 weeks 
than quetiapine monotherapy plus lamotrigine placebo 
in patients with bipolar depression. By using a factorial 
design, we also investigated the eff ects of addition of 
folic acid, which is a simple, widely available, over-the-
counter treatment, for which there is some evidence of 
effi  cacy in unipolar depression.11 Furthermore, folic acid 
is often included in vitamin pills as well as being recom-
mended during pregnancy especially when women are 
taking lamotrigine.12
Methods
Study design and participants
CEQUEL was a double-blind, randomised, placebo-
controlled, parallel group, 2 × 2 factorial trial undertaken 
across 27 sites in the UK (fi gure 1). The trial protocol is 
available from JRG. Eligible patients had bipolar disorder I 
or II diagnosed according to DSM-IV13 criteria on the basis 
of clinician interview, required new pharmacological 
treatment for an acute depressive episode, gave informed 
consent, and were aged 16 years or older (appendix). 
Additional criteria for entry to the randomised phase 
included ability to tolerate quetiapine at a dose of at least 
150 mg/day; uncertainty whether quetiapine plus 
lamotrigine would be more eff ective than quetiapine 
monotherapy; acceptable adherence to quetiapine (>90%); 
and were responding to the prompts to provide outcome 
data; willing to accept random allocation of treatments; 
and in the opinion of the investigator, not currently 
experiencing manic or mixed episode.
Written informed consent was obtained from every 
patient. The study was approved by each centre.
A number of protocol changes were made during the trial, 
all of which were approved by the Oxfordshire REC B ethics 
committee. The protocol initially approved was version 02. 
Protocol version 03 (December, 2008) included changes to 
procedures for distributing the investigational medicinal 
product. Protocol version 04 (March, 2009) included the 
addition of questions relating to use of health and social care 
resources and dose of lamotrigine 400 mg/day for women 
taking oral con traceptives. Version 05 included a change to 
primary outcome from binary “remission at 12 weeks” to 
con tinuous “greater improvement in depressive symptoms 
over 12 weeks”, a consequent reduction in sample size from 
584 to 236 and to allow immediate randomisation of patients 
already on quetiapine. Version 06 (May, 2013) included 
investigation of the eff ect of the folate hydrolase 
polymorphism on folic acid.
Randomisation and masking
After 7–14 days run-in on quetiapine, participants were 
randomly assigned (1:1) to added lamotrigine 
Research in context
Evidence before this study
During the planning phase of CEQUEL, we conducted a 
systematic review and individual patient data meta-analysis of 
randomised trials (Geddes et al, 2009).  The pooled analysis 
found a modest treatment eff ect for lamotrigine over an 8 
week period which was not observed in the individual trials.  
Added value of this study 
CEQUEL investigated the eff ect of lamotrigine compared with 
placebo over a longer time period than previous trials and as 
add-on therapy to quetiapine. CEQUEL also investigated the 
eff ects of folic acid compared to placebo in bipolar depression.  
Implications of all the available evidence 
Lamotrigine improves depressive symptoms in bipolar 
depression and the benefi ts are maintained for 52 weeks. 
Adding lamotrigine to quetiapine might be an eff ective and 
well tolerated option for many patients with bipolar depression. 
Folic acid may reduce the effi  cacy of lamotrigine.  Lamotrigine 
also reduced the risk of relapse in patients with bipolar 1 
disorder who have predominantly depressive episodes. CEQUEL 
should encourage clinicians and patients to consider 
lamotrigine for bipolar depression, but also to be aware that 
concurrent folic acid  might reduce its eff ectiveness.  
See Online for appendix
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200 mg/day (100 mg/day with concurrent valproate and 
400 mg/day with concurrent combined oral 
contraceptives) or placebo by a centralised random-
isation service by fax or web-based form. Lamotrigine 
was commenced at 25 mg daily and increased gradually 
to 200 mg as in the US FDA prescribing information.14 
Participants, clinicians, and researchers were masked to 
treatment allocation.
Participants not currently taking folic acid and with no 
contraindications to it were separately randomised to folic 
acid 500 μg/day or placebo. To enroll a patient, the treating 
physician faxed the randomisation form to the trial offi  ce. 
After establishing eligibility and that informed consent 
had been obtained, the patient was randomised, assigned a 
treatment pack number, and dispensed medication from 
the trial pharmacy. Randomisation used an adaptive 
minimisation algorithm balancing for centre, age, sex, 
bipolar disorder I or II, baseline severity of depression, 
quetiapine dose, concurrent medication, pretrial use of 
quetiapine, pretrial use of lamotrigine, and mood episodes 
in past year (<4 or ≥4). The minimisation algorithm was 
seeded by randomising the fi rst 60 participants using 
simple randomisation then introducing the minimisation 
algorithm. Allocated treatment was continued for 52 weeks 
and follow-up was continued even if trial-allocated 
treatment was discontinued.
Procedures
The severity of depressive symptoms was assessed with 
the Quick Inventory of Depressive Symptomatology—self 
report version (QIDS-SR16), which is a 16-item scale 
covering the DSM-IV criteria for depressive episode 
producing a score between 0 and 27.15 The QIDS-SR16 has 
been shown to agree well with the clinician-rated version 
in patients with bipolar depression and with other widely 
used depression rating scales such as the 24-item 
Hamilton Rating Scale for Depression.15–18 QIDS-SR16 
scores are categorised: ≤5 as no depression; 6–10 as mild 
depression; 11–15 as moderate depression; 16–20 as severe 
depression; and ≥21 as very severe depression. A 
minimum level of depressive symptoms was not required 
for entry to either run-in or randomised phases of the trial 
Figure 1: Trial profi le
266 entered run-in
202 randomly assigned
55 allocated to active lamotrigine plus 
placebo folic acid (including 8 not 
randomised into folic acid study)
30 discontinued lamotrigine
6 non-adherence
8 intolerance
2 new depressive episode
1 new manic episode
13 other/no reason
26 discontinued lamotrigine
6 non-adherence
2 intolerance
4 new depressive episode
14 other/no reason
24 discontinued lamotrigine
6 non-adherence
1 lack of efficacy
4 intolerance
1 adverse event
12 other/no reason
35 discontinued lamotrigine
5 non-adherence
2 lack of efficacy
9 intolerance
1 adverse effect
1 new manic episode
17 other/no reason
46 allocated to active lamotrigine plus 
active folic acid
55 allocated to placebo lamotrigine plus 
placebo folic acid (including 8 not 
randomised into folic acid study
44 included in analysis of primary 
outcome (12 ± 2 weeks)
11 exclusions
9 stopped providing follow-up 
data before 10 weeks
2 no data in range 12 ± 2 weeks
38 included in analysis of primary 
outcome (12±2 weeks)
8 exclusions
6 stopped providing follow-up 
data before 10 weeks
2 no data in range 12 ± 2 weeks
39 included in analysis of primary 
outcome (12 ± 2 weeks)
7 exclusions
7 stopped providing follow-up
data before 10 weeks
43 included in analysis of primary
outcome (12 ± 2 weeks)
12 exclusions
9 stopped providing follow-up
data before 10 weeks
3 no data in range 12 ± 2 weeks
32 had data available at 22 weeks
30 had data available at 52 weeks
31 had data available at 22 weeks
20 had data available at 52 weeks
29 had data available at 22 weeks
26 had data available at 52 weeks
32 had data available at 22 weeks
27 had data available at 52 weeks
64 withdrew from run-in phase
19 suspected reaction to or unable to tolerate quetiapine
14 no longer clinically eligible for randomisation (eg, had emergent manic symptoms, or
abnormal blood test results)
13 withdrew consent
 5 did not adhere to quetiapine and/or complete self-report scales
1 adverse event
12 other
46 allocated to placebo lamotrigine plus
active folic acid
For more on QIDS see http://
www.ids-qids.org
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because the relevant criterion was clinical judgement that 
new pharmacological treatment was required for a 
depressive episode. Manic symptoms were assessed with 
the Altman Self Rating Mania Scale (ASRM).19 Quality of 
life was measured at baseline and at 12 weeks and 
52 weeks with the EuroQol EQ-5D-3L.20 Data for symptoms 
and quality of life were provided by participants by the 
True Colours system via text message, email, or paper.21
Investigators were encouraged to withdraw any other 
treatments for mood symptoms that participants were 
taking before entry to the run-in phase, but these drugs 
could be continued where clinically indicated. Drug 
treatments that were not withdrawn were continued at 
the same dose for the duration of the trial unless there 
was a clinical need for change. All concurrent 
psychotropic medicines were recorded on the baseline 
assessment form and any subsequent changes reported. 
Carbamazepine (which decreases the serum level of 
lamotrigine) was stopped during the run-in phase or 
replaced by oxcarbazepine.
Additional treatment for depressive symptoms was not 
allowed during the fi rst 12 weeks of the randomised 
phase. After 12 weeks, new treatment for depressive 
symptoms could be initiated as clinically appropriate if a 
response to allocated treatment was considered to be 
inadequate or if new symptoms emerged. Folic acid 
(prescribed and over-the-counter preparations) was 
stopped unless there were reasons why the participant 
should not be randomised to folic acid or placebo.
All participants initially entered a 7–14 day active run-
in with quetiapine monotherapy to screen for adherence 
to quetiapine and to study procedures, tolerability, and 
symptom stability. Quetiapine was commenced at 
50 mg on days 1 and 2, increased to 100 mg on days 3 
and 4, 200 mg on days 5 and 6, and 300 mg on day 7 and 
beyond. The target dose of quetiapine was 300 mg, but 
if this was not tolerated a minimum dose of 150 mg was 
required for at least 3 days to proceed to randomisation. 
Quetiapine was continued at the established dose 
throughout the randomised phase unless there were 
clinical reasons to stop or the patient withdrew consent. 
Changes to the dose of quetiapine after randomisation 
were considered to be protocol non-compliant and 
when this occured the reason for the change was 
recorded. The run-in was included both to exclude 
patients with transient symptoms and to improve 
effi  ciency without jeopardising clinical applicability by 
deploying the combination in a stepped approach 
comparable with routine clinical practice.22 The fi rst 
participant was recruited on Oct 21, 2008, and the last 
patient completed follow-up on April 27, 2013. We also 
genotyped functional polymorphisms in genes involved 
in one-carbon pathways, and measured related 
biochemical indices; these results will be presented 
separately.
Outcomes
The primary outcome was depressive symptoms score 
at 12 weeks (±2 weeks) from randomisation using 
QIDS-SR16. The prespecifi ed primary analysis was 
assessed via a linear mixed eff ects model using data at 
12 weeks (±2), 22 (±2) weeks, and 52 (±2) weeks only. 
The model fi tted time and randomised group as fi xed 
eff ects and participants as random eff ect. An interaction 
between time and randomised group was fi tted to allow 
estimation of treatment eff ect at each timepoint. 
Analysis was by modifi ed intention-to-treat. That is, 
after randomisation, participants were analysed 
according to their allocated treatment group irrespective 
of what treatment they actually received. Assumptions 
for regression models were assessed graphically based 
on residuals. Participants who provided no data within 
these time windows were excluded. The model was 
adjusted for folic acid (active, placebo, or not allocated), 
baseline QIDS-SR16, baseline ASRM (≥6), bipolar 
disorder I or II, age, sex, dose of quetiapine (<300 mg/day 
or ≥300 mg/day), concurrent lithium, concurrent 
Placebo 
(n=101)
Lamotrigine 
(n=101)
Placebo 
(n=94)
Folic acid 
(n=92)
NA* 
(n=16)
Bipolar type
I 75 (74%) 74 (73%) 67 (71%) 69 (75%) 13 (81%)
II 26 (26%) 27 (27%) 27 (29%) 23 (25%) 3 (19%)
Age (years)
≤30 17 (17%) 19 (19%) 19 (20%) 17 (19%) 0
31–40 20 (20%) 25 (25%) 25 (27%) 17 (19%) 3 (19%)
41–50 32 (32%) 34 (34%) 26 (28%) 33 (36%) 7 (44%)
>50 32 (32%) 23 (23%) 24 (26%) 25 (27%) 6 (38%)
Sex
Male 46 (46%) 44 (44%) 41 (44%) 42 (46%) 7 (44%)
Female 55 (55%) 57 (56%) 53 (56%) 50 (54%) 9 (56%)
Dose of quetiapine (mg/day)
≤150 19 (19%) 19 (19%) 16 (17%) 21 (23%) 1 (6%)
>150–<300 14 (14%) 18 (18%) 20 (21%) 9 (10%) 3 (19%)
300 54 (54%) 55 (54%) 50 (53%) 50 (54%) 9 (56%)
>300 14 (14%) 9 (9%) 8 (9%) 12 (13%) 3 (19%)
Concurrent medication
Lithium 14 (14%) 12 (12%) 13 (14%) 12 (13%) 1 (6%)
Valproate 18 (18%) 24 (24%) 22 (23%) 18 (20%) 2 (13%)
Other mood stabiliser 2 (2%) 5 (5%) 2 (2%) 3 (3%) 2 (13%)
Olanzapine 4 (4%) 3 (3%) 5 (5%) 1 (1%) 1 (6%)
Other atypical antipsychotic 3 (3%) 4 (4%) 4 (4%) 3 (3%) 0
Conventional antipsychotic 3 (3%) 2 (2%) 1 (1%) 4 (4%) 0
Antidepressant 40 (40%) 29 (29%) 29 (31%) 33 (36%) 7 (44%)
Pretrial quetiapine 22 (22%) 25 (25%) 23 (25%) 21 (23%) 3 (19%)
Pretrial lamotrigine 1 (1%) 1 (1%) 1 (1%) 1 (1%) 0
Participants with mood episodes in 
past year
27 (27%) 26 (26%) 27 (29%) 24 (26%) 2 (13%)
Data are n (%). Participants were randomised to Lamotrigine or placebo, and additionally randomised to folic acid or 
placebo if included in that part of the study. Participants are therefore counted twice in this table. NA=not applicable. 
*Participants who chose not to be randomised into the folic acid component of the study.
Table 1: Baseline characteristics at randomisation 
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valproate, or concurrent antidepressant. The primary 
analysis of the folic acid comparison was conducted in 
the same way as for the lamotrigine comparison, but 
included only those randomised to the folic acid part of 
the study. Although an interaction between the 
interventions was not anticipated, this was investigated 
by adding an interaction term between the randomised 
treatments (lamotrigine x folic acid) to the model in the 
analysis of the primary outcome. The interaction 
analysis was restricted to participants who were 
randomised to both lamotrigine/placebo and folic acid/
placebo. In line with the primary analysis, a regression 
based approach adjusting for covariates was applied 
both for the lamotrigine and folic acid comparisons.
As a secondary analysis of the primary outcome, all 
weekly non-missing QIDS-SR16 scores between 
randomisation and week 52 were analysed with a mixed 
eff ects linear regression model to account for the repeated 
measures over time. The mixed eff ect model contained 
QIDS-SR16 score as the response variable, and time 
(week) as a continuous covariate to allow the slope of the 
regression line representing the change in outcome over 
time to be assessed. A time by lamotrigine interaction 
was included as a fi xed eff ect to allow estimation of the 
slope of the regression line to diff er according to 
treatment allocation. Treatment eff ect at each timepoint 
was derived similarly as described above. To incorporate 
the noted absence of linearity into the analysis, the 
regression model was segmented at 12 weeks and 
22 weeks and the slope at each point was allowed to vary.
Secondary outcomes included improvement in 
depressive symptoms at 52 weeks; proportion of 
participants in remission (QIDS-SR16 ≤5) at 12 weeks and 
52 weeks; time to new intervention for depressive and 
manic symptoms; self-harm; mortality; adverse events; 
and health-related quality of life. EQ-5D utility analyses 
were based on available cases and following multiple 
imputation of missing data.
The proportion of participants with manic symptoms, 
defi ned as ASRM scores 6 or higher at 12 weeks, 22 weeks, 
and 52 weeks after randomisation, was analysed with 
log-binomial regression models at each timepoint 
separately. The models included treatment by lamotrigine, 
treatment by folic acid (yes, no, or not applicable) and 
minimisation variables as for the primary analysis.
Statistical analysis
The sample size was calculated to detect a clinically 
important eff ect of lamotrigine on the primary outcome 
measure—ie, a 2·0 point diff erence (SD 5·4) in the 
QIDS-SR16. The calculation assumed a repeated 
measures analysis with 3 timepoints and a correlation 
between time points of 0·4 and also included a 20% loss 
to follow-up, yielding a total sample size of 236 (90% 
power and two-sided alpha 5%).
Data were analysed with SAS version 9.3 (SAS Institute 
Inc, Cary, NC, USA).
CEQUEL was registered with EUdraCT, number 
2007-004513-33; and approved by REC 08/H0605/39; 
with a clinical trial authorisation 20584/0234/001-0001 
and ISRCTN17054996.
Role of the funding source
This study was funded by the Medical Research Council. 
Some study drug was donated by GlaxoSmithKline. 
Neither funder had any role in the study design; data 
collection, analysis, or interpretation of data; writing of 
the report; or in the decision to submit the paper for 
publication.
Results
Between Oct 21, 2008, and April 27, 2012, 
202 participants were randomly assigned; 101 to 
lamotrigine and 101 to placebo (fi gure 1). Of 
266 participants who entered the run-in, 19 (7%) were 
unable to progress to randomisation due to adverse 
eff ects or inability to tolerate quetiapine. Baseline 
characteristics of randomised participants are 
summarised in table 1; about three-quarters of patients 
met criteria for bipolar type I. The aim was to balance 
groups for bipolar subtype, age, and sex, but some 
imbalances remained. The largest imbalance was the 
proportion using antidepressants at randomisation: 
more participants randomised to placebo were using 
Number of participants Mean (SD; 95% CI)
Lamotrigine vs placebo
Placebo
Baseline 101 15·0 (5·4; 13·9–16·0)
Week 12 81 12·5 (6·3; 11·1–13·8)
Week 22 63 11·6 (6·5; 10·0–13·2)
Week 52 47 12·0 (6·1; 10·2–13·8)
Lamotrigine
Baseline 101 15·3 (5·1; 14·3–16·3)
Week 12 83 10·9 (6·7; 9·4–12·3)
Week 22 61 9·6 (6·4; 7·9–11·2)
Week 52 56 9·2 (6·8; 7·4–11·1)
Folic acid vs placebo*
Placebo
Baseline 94 15·0 (5·5; 13·9–16·1)
Week 12 73 11·0 (6·6; 9·4–12·5)
Week 22 52 10·5 (6·2; 8·8–12·3)
Week 52 47 11·6 (6·9; 9·6–13·6)
Folic acid
Baseline 92 15·1 (5·4; 14·0–16·2)
Week 12 77 11·8 (6·3; 10·3–13·2)
Week 22 60 10·6 (6·8; 8·9–12·4)
Week 52 46 9·8 (6·5; 7·8–11·7)
QIDS-SR16=Quick Inventory of Depressive Symptomatology—self report 
version 16. *Folic acid versus placebo comparisons restricted to those participants 
who consented to separate randomisation.
Table 2: QIDS-SR16 summary statistics
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antidepressants compared with those randomised to 
lamotrigine. The direction of imbalance was reversed 
for the folic acid comparison, with slightly fewer 
participants using antidepressants at baseline in those 
who were randomised to placebo compared with those 
randomised to folic acid. Analyses were adjusted for 
these imbalances. About three quarters of participants 
were diagnosed with bipolar disease I and a quarter 
were diagnosed with bipolar disease II and the mean 
QIDS-SR16 score indicates moderate depression. The 
modal daily dose of quetiapine was 300 mg/day.
At 12 weeks, participants randomised to lamotrigine 
had lower QIDS- SR16 scores than those randomised to 
placebo (table 2; table 3; fi gure 2A). The mean diff erence 
between the groups was –1·73 points ([95% CI –3·57 to 
0·11]; p=0·066). A similar diff erence was seen at 22 weeks 
(–1·87 points [–3·92 to 0·17]; p=0·072; table 3; fi gure 2B). 
At 52 weeks, participants randomised to lamotrigine 
were on average 2·7 points lower on the QIDS scale 
(–2·69 ([95% CI –4·89 to –0·49]; p=0·017) than those 
randomised to placebo. Thus, mean QIDS-SR16 scores 
were consistently lower in participants taking lamotrigine 
than in those taking placebo (table 3).
Signifi cantly more participants treated with lamotrigine 
met criteria for remission (QIDS ≤5) at 12 weeks (26 [31%] 
in lamotrigine group vs 13 [16%] in placebo group; relative 
risk (RR) 2·11 [95% CI 1·09–4·07]; p=0·026) and at 
52 weeks (20 [36%] in lamotrigine group vs six [13%] in 
placebo group; RR 3·73 [1·35–10·29]; p=0·012).
The secondary analysis of the primary outcome, using 
all submitted scores over the 52 week follow up period 
resulted in similar fi ndings (data not shown). Depression 
scores decreased for those receiving lamotrigine more 
quickly than those receiving placebo resulting in an 
estimated diff erence at 12 weeks of –1·40 ([95% CI –2·9 
to 0·09]; p=0·066).
150 participants (all those available who were randomly 
assignedto folic acid study) were available for analysis of 
folic acid versus placebo at 12 weeks. Mean QIDS-SR16 
scores were no diff erent in those randomly assigned to 
folic acid than in those randomly assigned to placebo at 
12 weeks or at 22 weeks and 52 weeks (table 2; fi gure 2B).
Although an interaction between lamotrigine and folic 
acid had not been anticipated, it seemed that folic acid 
was associated with an impaired lamotrigine response in 
the fi rst 12 weeks.
Due to the interaction noted between treatments, the 
most reliable and unconfounded estimate of the eff ect 
of lamotrigine at 12 weeks is the estimate from the 
group not randomised to take folic acid. At 12 weeks, 
the mean diff erence in QIDS-SR16 on lamotrigine 
compared with placebo was –4·14 ([95% CI –6·90 to 
–1·37]; p=0·004) with no folic acid and 0·12 ([–2·58 to 
2·82]; p=0·931) with folic acid (fi gure 3).
There were no signifi cant diff erences in rates of new 
treatment (hospital admission or drug treatment) for 
depression between the treatment groups (31 [31%] in 
Figure 2: Observed and estimated mean QIDS-SR16 scores at key timepoints by comparisons for lamotrigine 
(A) and folic acid (B)
Error bars show 95% CI. QIDS-SR16=Quick Inventory of Depressive Symptomatology—self report version.
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Adjusted* mean 
diff erence (95% CI)
p value
Placebo vs lamotrigine
12 weeks (±2 weeks) –1·73 (–3·57 to 0·11) 0·066
22 weeks (±2 weeks) –1·87 (–3·92 to 0·17) 0·072
52 weeks (±2 weeks) –2·69 (–4·89 to –0·49) 0·017
Placebo vs folic acid
12 weeks (±2 weeks) 0·75 (–1·16 to 2·66) 0·441
22 weeks (±2 weeks) 0·17 (–1·97 to 2·30) 0·878
52 weeks (±2 weeks) –0·92 (–3·20 to 1·35) 0·423
*Adjusted for baseline QIDS-SR16, bipolar I or bipolar II, age (classifi ed as <40 years 
or ≥40 years), sex, dose of quetiapine (<300 mg/day or ≥300 mg/day), concurrent 
lithium, concurrent valproate, and concurrent antidepressant. Lamotrigine 
comparisons were adjusted for folic acid (active, placebo, or not applicable). Folic 
acid comparisons adjusted for lamotrigine (active or placebo). QIDS-SR16=Quick 
Inventory of Depressive Symptomatology—self report version 16.
Table 3: QIDS-SR16 adjusted mean diff erences from mixed eff ects 
regression model by time
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lamotrigine group vs 39 [39%] in placebo group; 
adjusted RR 0·84 [95% CI 0·58–1·24]) p=0·380) or folic 
acid compared with placebo (25 [27%] in folic acid 
group vs 37 [39%] in placebo group; adjusted RR 0·67 
[0·43–1·03]; p=0·065). There were no diff erences noted 
for new treatments for mania or mixed state between 
treatment groups (nine [9%] in lamotrigine group vs 12 
[12%] in placebo group; adjusted RR 0·67 [95% CI 
0·29–1·56]; p=0·35) or for folic acid compared with 
placebo (eight [9%] in folic acid group vs 11 [12%] in 
placebo group; adjusted RR 0·79 [0·33–1·89]; p=0·60). 
There was no clear increase in clinically signifi cant 
manic symptoms (manic relapse defi ned as ASRM ≥10) 
at any time with lamotrigine, although the event rate 
was low and the trial was not powered to evaluate this 
outcome reliably (appendix p 2). More participants on 
lamotrigine than on placebo reported some manic 
symptoms (ASRM ≥ 6) at 12 weeks (adjusted RR 2·59 
[95% CI 1·24–5·41]; p=0·012), but not at 22 weeks 
(adjusted RR 0·98 [0·38–2·54]; p=0·967) or at 52 weeks 
(0·94 [0·31–2·87]; p=0·92), refl ecting improved mood. 
Folic acid treatment showed no eff ect on mania scores 
(data not shown).
During the 12 months follow-up, health-related quality 
of life improved in all groups generally. No diff erence was 
seen for any of the group comparisons (appendix pp 3–4).
There were 32 serious adverse events in 24 randomised 
participants. These included one death by suicide (in 
the folic acid only group), 18 admissions to hospital for 
depression, mania, or other mood disorders involving 
15 participants (six participants allocated placebo only, 
three participants allocated lamotrigine only, two 
participants allocated folic acid only, and four 
participants allocated lamotrigine plus folic acid); and 
13 admissions to hospital in nine participants for other 
reasons; (three participants allocated placebo only, two 
participants allocated lamotrigine only, one participant 
allocated folic acid only, and three participants allocated 
lamotrigine plus folic acid). None were judged to be 
related to trial medication. 
There were 17 non-serious adverse events that led to 
withdrawal of treatment in 17 participants. Five were 
judged to be possible adverse reactions to trial 
medication (one participant allocated placebo only, two 
participants allocated lamotrigine only, one participant 
allocated folic acid only, and one participant allocated 
lamotrigine plus folic acid). Symptoms included nausea 
and stomach cramps, musculoskeletal pain, and 
oedema. For 12 participants, the adverse event was 
judged to be unrelated to trial medication (fi ve 
participants allocated placebo only, three participants 
allocated lamotrigine only, two participants allocated 
folic acid only and two participant allocated lamotrigine 
plus folic acid.
Table 2 shows the number of participants included at 
each timepoint but there are no data for adherence to 
treatment.
Discussion
The results of CEQUEL show that addition of lamotrigine 
to quetiapine for treatment of acute bipolar depression 
improves both mean depressive symptoms and rates of 
clinical remission compared with placebo at 12 weeks and 
52 weeks. Folic acid was no better than placebo in 
reducing depressive symptoms. There was a statistically 
signifi cant interaction between lamotrigine and folic acid 
at 12 weeks, with folic acid seeming to substantially 
reduce the eff ectiveness of lamotrigine. The result of this 
eff ect modifi cation was that the mean diff erence in 
QIDS-SR16 due to lamotrigine was reduced in the full 
sample (including participants on both active folic acid 
and folic acid placebo). Restricting the analysis at 12 weeks 
to those participants not allocated to folic acid produced 
an unbiased estimate of the eff ect of lamotrigine, which 
showed a statistically and clinically signifi cant mean 
reduction of 4·1 points (95% CI 1·37–6·90) on the 
QIDS-SR16, although the smaller sample size led to 
greater imprecision around the treatment eff ect. No 
benefi ts due to lamotrigine were observed on the 
secondary outcome measure of health-related quality of 
life, which might be due to lack of power.
The strengths of CEQUEL include the double-blind 
design and good retention rates (>80%) at 12 weeks. 
Almost all the patients recruited into CEQUEL were 
receiving lamotrigine for the fi rst time, which is a 
substantial strength of the study because the results are 
therefore able to inform treatment decisions in patients 
who have not had experience of the drug. The main 
weakness is the higher drop-out rate at 52 weeks, 
although this remains lower than often observed even in 
double-blind maintenance trials in this clinical 
population.23 Factorial trials, which can be an effi  cient 
way to evaluate two or more interventions, uncommonly 
identify interactions between treatments.24,25 In CEQUEL, 
there was a statistically and clinically signifi cant 
interaction, which shows some of the advantages and 
disadvantages of this design.26
 Figure 3: Forest plot showing within-group model estimates by timepoint 
and folic acid group
QIDS-SR16=Quick Inventory of Depressive Symptomatology—self report version.
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The interaction between folic acid and lamotrigine was 
unexpected and additional research is required to 
investigate this further. However, there are grounds to 
consider such an interaction biologically plausible. 
Lamotrigine was originally synthesised as one of a series of 
folate antagonists on the grounds that folate was thought 
to be pro-convulsant.6 Hence, it is possible that lamotrigine 
and folate both bind to a common receptor or enzyme site. 
Alternatively, it could be a pharmacokinetic eff ect whereby 
folic acid reduces absorption of lamotrigine from the 
gastrointestinal tract. There has been surprisingly little 
research into the mechanism(s) of action of lamotrigine to 
either include or exclude a possible important eff ect 
modifi cation by folic acid. We cannot fi nd any previous 
report of a clinical interaction of the kind we describe here, 
although the summary of product characteristics for 
lamotrigine does report an eff ect on folate levels. Whatever 
the cause, the interaction is potentially clinically important 
because folic acid supplementation might be more likely 
in some patient groups taking lamotrigine, for example 
pregnant women12 and as an adjunctive therapy in mood 
disorder.11 Furthermore, folic acid is present in the doses 
used in CEQUEL in many over-the-counter vitamin 
preparations. One clinically important conclusion from 
CEQUEL is that if a patient with bipolar disorder needs 
folic acid therapy, then lamotrigine should be avoided (and 
vice versa). The result raises an intriguing question about 
the likely effi  cacy of lamotrigine in countries which fortify 
wheat fl ower with folic acid: the US programme has been 
estimated to provide 100–200 μg of folic acid per day in 
women of childbearing age.27 It is unclear if this amount is 
suffi  cient to reduce the treatment eff ect.
CEQUEL confi rms the effi  cacy, in the absence of folic 
acid, of adding lamotrigine to quetiapine in bipolar 
depression and that the benefi ts persist for 52 weeks. 
These fi ndings complement another independent trial, 
which showed clinical benefi t for lamotrigine combination 
therapy, although in that case in combination with 
lithium.10 Together with the pooled data of lamotrigine 
versus placebo,9 it seems that lamotrigine is an eff ective 
treatment in bipolar depression. Guidelines have varied in 
their recommendation of lamotrigine as a fi rst choice 
option for treating bipolar depression because of the 
uncertainties remaining from the industry sponsored 
trials. They either suggest using lamotrigine monotherapy 
as a fi rst line treatment option28 or as a second line option 
or following non-response to initial therapy.4 CEQUEL is 
an important addition to the evidence base that informs 
clinical practice because it suggests that adding 
lamotrigine to quetiapine may be an eff ective and well 
tolerated option for many patients with bipolar depression.
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